Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells 114,367 Shares of Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Ryan Savitz sold 114,367 shares of Dianthus Therapeutics stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $83.00, for a total transaction of $9,492,461.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Dianthus Therapeutics Stock Up 2.9%

DNTH traded up $2.46 during trading hours on Thursday, reaching $87.02. 56,787 shares of the company’s stock traded hands, compared to its average volume of 1,060,620. The firm has a 50-day moving average price of $62.49 and a 200 day moving average price of $47.35. Dianthus Therapeutics, Inc. has a 52-week low of $13.36 and a 52-week high of $88.49. The firm has a market capitalization of $3.87 billion, a PE ratio of -21.08 and a beta of 1.56.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Monday, March 9th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.46). Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%. The company had revenue of $0.57 million during the quarter, compared to analysts’ expectations of $0.40 million. Equities analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on DNTH shares. Wedbush lifted their price objective on shares of Dianthus Therapeutics from $55.00 to $80.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 10th. Truist Financial increased their price target on Dianthus Therapeutics from $63.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, March 9th. Robert W. Baird upped their price objective on shares of Dianthus Therapeutics from $67.00 to $132.00 and gave the company an “outperform” rating in a report on Tuesday, March 10th. William Blair reiterated an “outperform” rating on shares of Dianthus Therapeutics in a research note on Monday, March 16th. Finally, Oppenheimer increased their price objective on Dianthus Therapeutics to $145.00 and gave the company an “outperform” rating in a report on Monday, March 9th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Dianthus Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $117.30.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of large investors have recently made changes to their positions in the stock. Patient Square Capital LP purchased a new stake in shares of Dianthus Therapeutics in the third quarter valued at about $4,919,000. Vanguard Group Inc. lifted its position in Dianthus Therapeutics by 13.6% in the third quarter. Vanguard Group Inc. now owns 1,642,198 shares of the company’s stock valued at $64,620,000 after buying an additional 196,117 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Dianthus Therapeutics in the 2nd quarter valued at approximately $503,000. Braidwell LP purchased a new position in shares of Dianthus Therapeutics during the 3rd quarter worth approximately $32,859,000. Finally, Fairmount Funds Management LLC increased its holdings in Dianthus Therapeutics by 22.2% in the 3rd quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock valued at $130,138,000 after purchasing an additional 600,000 shares during the last quarter. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.